The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease.
Ontology highlight
ABSTRACT: Inherited retinal degenerations (IRDs) are a diverse group of conditions that are often characterized by the loss of photoreceptors and blindness. Recent innovations in molecular biology and genomics have allowed us to identify the causative defects behind these dystrophies and to design therapeutics that target specific mechanisms of retinal disease. Recently, the FDA approved the first in vivo gene therapy for one of these hereditary blinding conditions. Current clinical trials are exploring new therapies that could provide treatment for a growing number of retinal dystrophies. While the field has had early success with gene augmentation strategies for treating retinal disease based on loss-of-function mutations, many novel approaches hold the promise of offering therapies that span the
SUBMITTER: Martinez Velazquez LA
PROVIDER: S-EPMC8583900 | biostudies-literature | 2021 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA